A Phase I, Open-label, Non-randomized, Dose-finding, Safety, Tolerance, and Pharmacokinetic Study of Orally Administered S-1 in Combination with Gemcitabine and Erlotinib in Patients with Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2009
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Erlotinib; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics
- 29 Sep 2009 New trial record